For the base business (Gland), quarterly revenue increased 1% YoY, with half-yearly revenue up 2%. Quarterly EBITDA for the base business grew 3% YoY, and half-yearly EBITDA increased 12%, with both maintaining margins at 35%. Shares of Gland Pharma Ltd ended at ₹1,969.25, up by ₹39.75, or 2.06%, on the BSE.
